A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib

NCT07689201 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Neoplasms

Interventions

DRUG: Velzatinib

Sponsor

GlaxoSmithKline